Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2023

Open Access 01-12-2023 | Prostate Cancer | Research

Overexpression of DDX49 in prostate cancer is associated with poor prognosis

Authors: Junyue Tao, Qintao Ge, Jialing Meng, Chaozhao Liang, Zongyao Hao, Jun Zhou

Published in: BMC Urology | Issue 1/2023

Login to get access

Abstract

Background

There is increasing evidence that DEAD-box helicases (DDX) can act either as promoters or suppressors in various cancer types. Nevertheless, the function of DDX49 in prostate cancer (PCa) is unknown. This study reveals the prognostic and predictive value of DDX49 in PCa.

Methods

First, we evaluated the expression of DDX49 between PCa and normal tissues based on TCGA and GEO databases. Univariate and multivariate regression analyses were conducted to reveal the risk factors for PCa recurrence. A K–M curve was employed to assess the relationship between DDX49 and recurrence-free survival. In vitro, DDX49 expression was evaluated in PCa and normal prostate cell lines. Furthermore, we constructed a shDDX49 lentivirus to knock down the expression of DDX49. Celigo® Image Cytometer and MTT assay were performed to analyse cell proliferation in PC-3 cells. Cell cycle distribution was detected with flow cytometry analysis. Apoptosis affected by the lack of DDX49 was metred with the PathScan® Stress and Apoptosis Signalling Antibody Array Kit.

Results

This study shows a high increase in DDX49 in PCa tissues in comparison with normal tissues and that increased DDX49 indicates a poor prognosis among PCa patients. Meanwhile, DDX49 knockdown suppressed the proliferation and migration of PC-3 cells, causing cell cycle arrest in the G1 phase. Stress and apoptosis pathway analysis revealed that the phosphorylation of HSP27, p53, and SAPK/JNK was reduced in the DDX49 knockdown group compared with the control group.

Conclusions

In summary, these results suggest that high expression of DDX49 predicts a poor prognosis among PCa patients. Downregulation of DDX49 can suppress cell proliferation, block the cell cycle, and facilitate cell apoptosis. Therefore, knockdown of DDX49 is a promising novel therapy for treating patients with PCa.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prost Cancer Prostatic Dis. 2019;22(1):24–38.CrossRef
3.
Barata PC, Sartor AO. Metastatic castration-sensitive prostate cancer: abiraterone, docetaxel, or. Cancer. 2019;125(11):1777–88.CrossRefPubMed
4.
5.
Daniel M, Knutson TP, Sperger JM, Li Y, Singh A, Stahlfeld CN, Passow C, Auch B, Lang JM, et al. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer. Endocr Relat Cancer. 2021;28(9):645–55.CrossRefPubMedPubMedCentral
6.
Cargill M, Venkataraman R, Lee S. DEAD-Box RNA helicases and genome stability. Genes (Basel). 2021;12(10):1471.CrossRefPubMed
7.
Cai W, Xiong Chen Z, Rane G, Satendra Singh S, Choo Z, Wang C, Yuan Y, Zea Tan T, Arfuso F, Yap CT, et al. Wanted DEAD/H or alive: helicases winding up in cancers. J Natl Cancer Inst. 2017;109(6):djw278.CrossRef
8.
Linder P, Jankowsky E. From unwinding to clamping: the DEAD box RNA helicase family. Nat Rev Mol Cell Biol. 2011;12(8):505–16.CrossRefPubMed
9.
Abdelhaleem M. Do human RNA helicases have a role in cancer? Biochim Biophys Acta. 2004;1704(1):37–46.PubMed
10.
Tanaka K, Okamoto S, Ishikawa Y, Tamura H, Hara T. DDX1 is required for testicular tumorigenesis, partially through the transcriptional activation of 12p stem cell genes. Oncogene. 2009;28(21):2142–51.CrossRefPubMed
11.
George RE, Kenyon R, McGuckin AG, Kohl N, Kogner P, Christiansen H, Pearson AD, Lunec J. Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer. 1997;33(12):2037–42.CrossRefPubMed
12.
Sun Z, Wang L, Eckloff BW, Deng B, Wang Y, Wampfler JA, Jang J, Wieben ED, Jen J, You M, et al. Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. BMC Med Genom. 2014;7:32.CrossRef
13.
Liu S, He L, Wu J, Wu X, Xie L, Dai W, Chen L, Xie F, Liu Z. DHX9 contributes to the malignant phenotypes of colorectal cancer via activating NF-kappaB signaling pathway. Cell Mol Life Sci. 2021;78(24):8261–81.CrossRefPubMed
14.
Liu M, Roth A, Yu M, Morris R, Bersani F, Rivera MN, Lu J, Shioda T, Vasudevan S, Ramaswamy S, et al. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev. 2013;27:2543–8.CrossRefPubMedPubMedCentral
15.
Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, et al. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res. 2008;68(19):7938–46.CrossRefPubMedPubMedCentral
16.
Vellky JE, McSweeney ST, Ricke EA, Ricke WA. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: a mechanism of castration resistance. Proc Natl Acad Sci U S A. 2020;117(45):28092–101.CrossRefPubMedPubMedCentral
17.
Yu W, Ma H, Li J, Ge J, Wang P, Zhou Y, Zhang J, Shi G. DDX52 knockdown inhibits the growth of prostate cancer cells by regulating c-Myc signaling. Cancer Cell Int. 2021;21(1):430.CrossRefPubMedPubMedCentral
18.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102.CrossRefPubMedPubMedCentral
19.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.CrossRefPubMed
20.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.CrossRefPubMedPubMedCentral
21.
22.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.CrossRefPubMed
23.
Zhang A, Yan G, Han Y, Wang X. Metabolomics approaches and applications in prostate cancer research. Appl Biochem Biotechnol. 2014;174(1):6–12.CrossRefPubMed
24.
Achard V, Putora PM, Omlin A, Zilli T, Fischer S. Metastatic prostate cancer: treatment options. Oncology. 2022;100(1):48–59.CrossRefPubMed
25.
Roviello G, Corona SP, Bonetta A, Cappelletti MR, Generali D. Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer. Onco Targets Ther. 2017;10:3811–5.CrossRefPubMedPubMedCentral
26.
Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.CrossRef
27.
Cordin O, Banroques J, Tanner NK, Linder P. The DEAD-box protein family of RNA helicases. Gene. 2006;367:17–37.CrossRefPubMed
28.
Sokolov M, Neumann R. Global gene expression alterations as a crucial constituent of human cell response to low doses of ionizing radiation exposure. Int J Mol Sci. 2015;17(1):55.CrossRefPubMedPubMedCentral
29.
30.
31.
Heerma van Voss MR, van Diest PJ, Raman V. Targeting RNA helicases in cancer: the translation trap. Biochim Biophys Acta Rev Cancer. 2017;1868(2):510–20.CrossRefPubMed
32.
Awasthi S, Verma M, Mahesh A, K Khan MI, Govindaraju G, Rajavelu A, Chavali PL, Chavali S, Dhayalan A. DDX49 is an RNA helicase that affects translation by regulating mRNA export and the levels of pre-ribosomal RNA. Nucleic Acids Res. 2018;46(12):6304–17.CrossRefPubMedPubMedCentral
33.
Lian X, Xiang D, Peng C, Chen J, Liao M, Sun G, Zhang Z. DDX49 is a novel biomarker and therapeutic target for lung cancer metastases. J Cell Mol Med. 2020;24(1):1141–5.CrossRefPubMed
34.
Apostolou P, Toloudi M, Papasotiriou I. Identification of genes involved in breast cancer and breast cancer stem cells. Breast Cancer (Dove Med Press). 2015;7:183–91.PubMed
35.
Dai H, Feng J, Nan Z, Wei L, Lin F, Jin R, Zhang S, Wang X, Pan L. Morphine may act via DDX49 to inhibit hepatocellular carcinoma cell growth. Aging (Albany NY). 2021;13(9):12766–79.CrossRefPubMed
36.
37.
Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, Morrione A, Giordano A, Cenciarelli C. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703.CrossRefPubMedPubMedCentral
38.
Ziouziou H, Paris C, Benizri S, Le TK, Andrieu C, Nguyen DT, Appavoo A, Taieb D, Brunel F, Oueslati R, et al. Nucleoside-lipid-based nanoparticles for phenazine delivery: a new therapeutic strategy to disrupt Hsp27-eIF4E interaction in castration resistant prostate cancer. Pharmaceutics. 2021;13(5):623.CrossRefPubMedPubMedCentral
39.
Cruciat CM, Dolde C, de Groot RE, Ohkawara B, Reinhard C, Korswagen HC, Niehrs C. RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wnt-beta-catenin signaling. Science. 2013;339(6126):1436–41.CrossRefPubMed
Metadata
Title
Overexpression of DDX49 in prostate cancer is associated with poor prognosis
Authors
Junyue Tao
Qintao Ge
Jialing Meng
Chaozhao Liang
Zongyao Hao
Jun Zhou
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2023
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-023-01251-4

Other articles of this Issue 1/2023

BMC Urology 1/2023 Go to the issue

Research

Assessment of bladder pressure and discomfort symptoms: How do overactive bladder differ from interstitial cystitis/bladder pain syndrome patients?

Research

First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study

Research

Machine learning-based prediction model and visual interpretation for prostate cancer

Research

Predictive value of systematic immune-inflammation index combined with Ki-67 index on prognosis of prostate cancer patients after laparoscopic radical prostatectomy

Research

Prognostic value of IKBIP in papillary renal cell carcinoma

Case report

Robotic partial cystectomy with excision of mesh after inguinal hernia repair: a case report